Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs in R&D
Published in: Drugs in R&D 1/2003

01-01-2003 | Adis R&D Profile

Talaporfin

LS 11, LS11, ME 2906, Mono-L-Aspartyl Chlorin e6, NP e6, NPE 6, Taporfin Sodium

Published in: Drugs in R&D | Issue 1/2003

Login to get access

Excerpt

Talaporfin [ME 2906, taporfin, LS 11, mono-L-aspartyl chlorin e6, NPE 6, NP e6] is a photosensitiser for use in photodynamic therapy, and consists of chlorin e6 in chlorophyll and L-aspartic acid.1 It was developed by Nippon Petrochemicals and is licensed to Meiji Seika with exclusive marketing rights for Japan and South East Asia. Talaporfin is injected into tumours and other target tissues where it accumulates. It is activated with light emitting diodes (LEDs) rather than with laser light as with other photosensitisers. Talaporfin has completed phase I clinical trials in the US for the treatment of superficial malignant tumours and is undergoing phase II trials in Japan for the treatment of various cancers. Meiji Seika has submitted an NDA to the Japanese authorities for marketing approval of talaporfin in patients with early-stage lung cancer. …
Footnotes
1
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
 
Literature
1.
Kostenich GA, Zhuravkin IN, Zhavrid EA. Chlorin-E(6) pharmacokinetics, toxicity and antitumor efficiency in photodynamic treatment of Wistar rats with sarcoma-M-1. Eksperimentalnaya Onkologiya. 15: 64–69, No. 5, 1993.
2.
Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clinical Cancer Research 4: 2741–2746, Nov 1998.PubMed
3.
Song L-MWK, Wang KK, Zinsmeister AR. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy admininstered to a human cholangiocarcinoma model. Cancer 82: 421–427, 15 Jan 1998CrossRef
4.
McMahon KS, Wieman TJ, Moore PH, et al. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Research 54: 5374–5379, 15 Oct 1994PubMed
Metadata
Title
Talaporfin
LS 11, LS11, ME 2906, Mono-L-Aspartyl Chlorin e6, NP e6, NPE 6, Taporfin Sodium
Publication date
01-01-2003
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 1/2003
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.2165/00126839-200304010-00014

Other articles of this Issue 1/2003

Drugs in R&D 1/2003 Go to the issue

Adis R&D Profile

Trabectedin

Original Research Article

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease

Adis R&D Profile

Morphine/Dextromethorphan — Endo

Adis R&D Profile

MT 100

Adis R&D Profile

Testosterone-Buccal — Columbia

Adis R&D Profile

Ferumoxtran-10